3 recruiting, 2 suspended, 1 not yet recruiting, 1 terminated. 7 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Recruiting 3, Suspended 2, Not yet recruiting 1, Terminated 1 |
| Phase 1 | 3 | Suspended 2, Recruiting 1 |
Follow Emavusertib: new trials by email Literature Review of Emavusertib trials Research Report on Emavusertib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Trial Comparing Three Different Treatment Options for Adults With Low-Risk Myelodysplasia and Anemia (A MyeloMATCH Treatment Trial) Biospecimen Collection, Bone Marrow Aspiration, Emavusertib - Myelodysplastic Syndrome | Phase 2 | Not yet recruiting | National Cancer Institute (NCI) | 270 | 2026-12-18 | 2026-09-22 |
| CA-4948 in Combination With Pembrolizumab and Stereotactic Radiosurgery to Improve Treatment of Melanoma Brain Metastases Emavusertib, Pembrolizumab, Stereotactic Radiosurgery - Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma | Phase 1 / Phase 2 | Suspended | Mayo Clinic | 23 | 2026-11-30 | 2026-10-20 |
| A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies Emavusertib, Zanubrutinib - Chronic Lymphocytic Leukemia, B-cell Malignancies | Phase 2 | Recruiting | Curis, Inc. | 108 | 2026-04-23 | 2026-06-12 |
| MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial) Allogeneic Hematopoietic Stem Cell Transplantation, Azacitidine, Best Practice - Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm | Phase 2 | Recruiting | National Cancer Institute (NCI) | 2000 | 2024-06-18 | 2026-11-02 |
| Treatment of Anemia in Patients With Very Low, Low or Intermediate Risk Myelodysplastic Syndromes With CA-4948 CA-4948 - Myelodysplastic Syndromes, Anemia | Phase 2 | Terminated | University of Leipzig | 38 | 2022-01-01 | 2024-08-13 |
| Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS) Emavusertib, Venetoclax - Acute Myelogenous Leukemia, Myelodysplastic Syndrome | Phase 1 / Phase 2 | Suspended | Curis, Inc. | 366 | 2020-07-06 | 2026-03-19 |
| CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL) Emavusertib, Ibrutinib - Relapsed Hematologic Malignancy, Refractory Hematologic Malignancy | Phase 1 / Phase 2 | Recruiting | Curis, Inc. | 152 | 2017-12-28 | 2026-10-06 |
Myelodysplastic Syndromes (4) · Leukemia, Myeloid, Acute (2) · Recurrence (2) · Anemia (1) · Brain Neoplasms (1) · Hematologic Neoplasms (1) · Hereditary Sensory and Autonomic Neuropathies (1) · Immune System Diseases (1) · Immunoproliferative Disorders (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Lymphatic Diseases (1) · Lymphoma (1) · Lymphoma, Non-Hodgkin (1) · Lymphoproliferative Disorders (1) · Melanoma (1)
Curis, Inc. (3) · National Cancer Institute (NCI) (2) · Mayo Clinic (1) · University of Leipzig (1)
United States (5) · Italy (3) · Spain (3) · Czechia (2) · France (2) · Germany (2) · Israel (2) · Poland (2) · Canada (1) · Puerto Rico (1)
Bently Doonan, MD, MS (1) · Jerald P Radich (1) · Rena J Buckstein (1) · Uwe Platzbecker, Prof. Dr. (1)
2025 (1), U10CA180863 (1), U10CA180888 (1)